ClinicalTrials.gg
CompletedNCT00854360Updated May 22, 2012Results posted

Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR

A Phase 2 interventional study of Beclomethasone dipropionate HFA Nasal Aerosol and Placebo in Seasonal Allergic Rhinitis and Hayfever, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 26 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2012-05-22.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
487
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 107 studies in Rhinitis, Allergic, Seasonal with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Rhinitis, Allergic, Seasonal · United States.

Enrollment
48th of 101
487 · median 446
Started
2009
with 12 others
Phase 2
20 of 107
none open now
Registered
54th of 107
by date
Lead sponsor
4 of 107
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, this one is the 48th largest by enrollment of the 101 interventional ones that give a count, is one of 13 that started in 2009, is one of 20 in phase 2, and was the 54th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

1 of the 107 studies in Rhinitis, Allergic, Seasonal with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Rhinitis, Allergic, Seasonal with a site in United States, or all of them as a file.
02

Study summary

This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group, 2-week, multi-center, dose-range-finding study in male or female patients (12 years and older) with SAR.

03

Conditions studied

  • Seasonal Allergic Rhinitis
  • Hayfever

Keywords

  • Seasonal Allergic Rhinitis
  • Hayfever
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female patients 12 years of age and older, as of the Screening Visit (SV).
  • General good health, and free of any concomitant conditions or treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the patient at increased risk during the study.
  • A history of SAR to relevant seasonal allergen (tree/grass pollen) for a minimum of two years immediately preceding the study Screening Visit (SV). The SAR must have been of sufficient severity to have required treatment (either continuous or intermittent) in the past and in the investigator's judgment is expected to be exposed to the allergen and require treatment throughout the entire study period.
  • A demonstrated sensitivity to relevant tree/grass pollen known to produce SAR through a standard skin prick test. A positive test is defined as a wheal diameter at least 3 mm larger than the control wheal for the skin prick test. Documentation of a positive result within 12 months prior to Screening Visit (SV) is acceptable.
  • Other criteria apply

Key Exclusion Criteria:

  • Participation in any drug study within the 30 days preceding the Screening Visit (SV) or planned participation in another investigational drug study at any time during this study.
  • History of physical findings of nasal pathology, including nasal polyps or other respiratory tract malformations, recent nasal , nasal trauma or surgery, atrophic rhinitis, or rhinitis medicamentosa (all within the last 60 days prior to the SV).
  • History of a respiratory infection or disorder [including, but not limited to bronchitis, pneumonia, chronic sinusitis, influenza, severe acute respiratory syndrome (SARS)] within the 14 days preceding the Screening Visit (SV), or development of a respiratory infection during the Run-in Period.
  • Use of any prohibited concomitant medications within the prescribed (per protocol) time since the last dosing period prior to the Screening Visit (SV) and/or plans for use during the entire treatment duration.
  • Other criteria apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
487 participants (actual)

Study arms

  • Experimental
    BDP HFA 80 µg/day

    During the 2-week double-blind Treatment Period participants self-administered two actuations (one per nostril) of 40 micrograms (µg) BDP HFA and two actuations of placebo HFA once daily.

    Drug: Beclomethasone dipropionate HFA Nasal Aerosol · Drug: Placebo

  • Experimental
    BDP HFA 160 µg/day

    During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of 40 µg BDP HFA once daily.

    Drug: Beclomethasone dipropionate HFA Nasal Aerosol

  • Experimental
    BDP HFA 320 µg/day

    During the 2-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.

    Drug: Beclomethasone dipropionate HFA Nasal Aerosol

  • Placebo comparator
    Placebo

    During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period

    Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 12 hours twice daily (AM \& PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.

    Time frame: Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)

Secondary outcomes

  1. Change From Baseline in Average AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two Week Treatment Period

    Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the 10 minutes prior to the assessment, twice daily (AM \& PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of symptom, bothersome but tolerable); 3=severe (symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.

    Time frame: Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)

  2. Change From Baseline in Morning Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two-week Treatment Period

    Change from Baseline in the morning patient-reported instantaneous TNSS. Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 10 minutes (prior to the assessment) in the morning on a scale from 0 (mild symptoms) to 3 (severe symptoms). The total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.

    Time frame: Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)

  3. Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)

    The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. A negative change from Baseline score indicates symptom improvement.

    Time frame: Baseline and Week 2

  4. Change From Baseline in Morning 24-hour Reflective Ocular Symptom Score Over the Two-week Treatment Period

    Participants recorded the severity of their symptoms (itching/burning eyes, tearing/watering eyes and redness of eyes) for the past 24 hours each morning using the following scale: 0=absent (no sign/symptoms); 1=mild (sign/symptom present, minimal awareness, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptom hard to tolerate, interfere with daily activities or sleeping). The total ocular symptom score (sum of 3 symptom scores) ranges from 0 to 9 (worst symptoms). A negative change from Baseline score indicates symptom improvement.

    Time frame: Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)

  5. Change From Baseline in Morning 24-hour Reflective Non-nasal Symptom Score Over the Two-week Treatment Period

    Participants recorded the severity of their symptoms (itching/burning eyes, tearing/watering eyes, redness of eyes and itching of ears or palate) for the past 24 hours each morning using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (symptoms hard to tolerate, interfere with daily activities or sleeping). Total non-nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.

    Time frame: Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)

07

Results

Posted May 22, 2012

Participant flow

A total of 685 patients were screened and 635 were enrolled in the study and participated in the Run-in Period. Of the 635 enrolled patients, 487 were randomized to treatment. The study was performed in the spring during tree and grass pollen seasons.

Participant flow — Overall Study
MilestoneBDP HFA 80 µg/DayBDP HFA 160 µg/DayBDP HFA 320 µg/DayPlacebo
Started118123122124
Intent to treat / safety population118123122123
Completed116120120114
Not completed23210
Withdrew: Adverse event0126
Withdrew: Withdrawal by subject0001
Withdrew: Pregnancy0100
Withdrew: Lack of efficacy2100
Withdrew: Other0003

Outcome measures

PrimaryChange From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period

Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 12 hours twice daily (AM \& PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.

Time frame:
Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period
units on a scaleBDP HFA 80 µg/DayBDP HFA 160 µg/DayBDP HFA 320 µg/DayPlacebo
Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period-1.88 ± 0.18-1.87 ± 0.18-2.22 ± 0.18-1.59 ± 0.18
Statistical analysis
  • BDP HFA 80 µg/Day vs Placebo · Repeated measures ANCOVA · p = 0.255 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: -0.29 · 95% CI -0.80 to 0.21The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
  • BDP HFA 160 µg/Day vs Placebo · Repeated measures ANCOVA · p = 0.257 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: -0.29 · 95% CI -0.78 to 0.21The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
  • BDP HFA 320 µg/Day vs Placebo · Repeated measures ANCOVA · p = 0.013 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: -0.63 · 95% CI -1.13 to -0.13The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
SecondaryChange From Baseline in Average AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two Week Treatment Period

Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the 10 minutes prior to the assessment, twice daily (AM \& PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of symptom, bothersome but tolerable); 3=severe (symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.

Time frame:
Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Average AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two Week Treatment Period
units on a scaleBDP HFA 80 µg/DayBDP HFA 160 µg/DayBDP HFA 320 µg/DayPlacebo
Change From Baseline in Average AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two Week Treatment Period-1.77 ± 0.18-1.71 ± 0.18-2.10 ± 0.18-1.50 ± 0.18
Statistical analysis
  • BDP HFA 80 µg/Day vs Placebo · Repeated measures ANCOVA · p = 0.278 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: -0.27 · 95% CI -0.77 to 0.22The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
  • BDP HFA 160 µg/Day vs Placebo · Repeated measures ANCOVA · p = 0.385 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: -0.22 · 95% CI -0.70 to 0.27The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
  • BDP HFA 320 µg/Day vs Placebo · Repeated Measures ANCOVA · p = 0.016 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: -0.60 · 95% CI -1.09 to -0.11The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
SecondaryChange From Baseline in Morning Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two-week Treatment Period

Change from Baseline in the morning patient-reported instantaneous TNSS. Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 10 minutes (prior to the assessment) in the morning on a scale from 0 (mild symptoms) to 3 (severe symptoms). The total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.

Time frame:
Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Morning Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two-week Treatment Period
units on a scaleBDP HFA 80 µg/DayBDP HFA 160 µg/DayBDP HFA 320 µg/DayPlacebo
Change From Baseline in Morning Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two-week Treatment Period-1.76 ± 0.18-1.71 ± 0.18-2.14 ± 0.18-1.31 ± 0.18
Statistical analysis
  • BDP HFA 80 µg/Day vs Placebo · Repeated measures ANCOVA · p = 0.082 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: -0.45 · 95% CI -0.95 to 0.06The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
  • BDP HFA 160 µg/Day vs Placebo · Repeated measures ANCOVA · p = 0.114 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: -0.40 · 95% CI -0.90 to 0.10The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
  • BDP HFA 320 µg/Day vs Placebo · Repeated measures ANCOVA · p = 0.001 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: -0.83 · 95% CI -1.33 to -0.33The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
SecondaryChange From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)

The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. A negative change from Baseline score indicates symptom improvement.

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · units on a scale
Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
units on a scaleBDP HFA 80 µg/DayBDP HFA 160 µg/DayBDP HFA 320 µg/DayPlacebo
Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)-1.30 ± 0.17-1.33 ± 0.15-1.62 ± 0.17-1.22 ± 0.16
Statistical analysis
  • BDP HFA 80 µg/Day vs Placebo · ANCOVA · p = 0.747 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: -0.07 · 95% CI -0.52 to 0.37Results obtained from ANCOVA with treatment, baseline and center in the model.
  • BDP HFA 160 µg/Day vs Placebo · ANCOVA · p = 0.605 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: -0.11 · 95% CI -0.53 to 0.31Results obtained from ANCOVA with treatment, baseline and center in the model.
  • BDP HFA 320 µg/Day vs Placebo · ANCOVA · p = 0.083 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: -0.39 · 95% CI -0.84 to 0.05Results obtained from ANCOVA with treatment, baseline and center in the model.
SecondaryChange From Baseline in Morning 24-hour Reflective Ocular Symptom Score Over the Two-week Treatment Period

Participants recorded the severity of their symptoms (itching/burning eyes, tearing/watering eyes and redness of eyes) for the past 24 hours each morning using the following scale: 0=absent (no sign/symptoms); 1=mild (sign/symptom present, minimal awareness, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptom hard to tolerate, interfere with daily activities or sleeping). The total ocular symptom score (sum of 3 symptom scores) ranges from 0 to 9 (worst symptoms). A negative change from Baseline score indicates symptom improvement.

Time frame:
Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Morning 24-hour Reflective Ocular Symptom Score Over the Two-week Treatment Period
units on a scaleBDP HFA 80 µg/DayBDP HFA 160 µg/DayBDP HFA 320 µg/DayPlacebo
Change From Baseline in Morning 24-hour Reflective Ocular Symptom Score Over the Two-week Treatment Period-1.16 ± 0.16-1.11 ± 0.16-1.46 ± 0.16-1.17 ± 0.16
Statistical analysis
  • BDP HFA 80 µg/Day vs Placebo · Repeated measures ANCOVA · p = 0.989 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: -0.00 · 95% CI -0.45 to 0.46The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
  • BDP HFA 160 µg/Day vs Placebo · Repeated measures ANCOVA · p = 0.808 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: -0.06 · 95% CI -0.39 to 0.50The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
  • BDP HFA 320 µg/Day vs Placebo · Repeated measures ANCOVA · p = 0.195 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: -0.29 · 95% CI -0.74 to 0.15The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
SecondaryChange From Baseline in Morning 24-hour Reflective Non-nasal Symptom Score Over the Two-week Treatment Period

Participants recorded the severity of their symptoms (itching/burning eyes, tearing/watering eyes, redness of eyes and itching of ears or palate) for the past 24 hours each morning using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (symptoms hard to tolerate, interfere with daily activities or sleeping). Total non-nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.

Time frame:
Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Morning 24-hour Reflective Non-nasal Symptom Score Over the Two-week Treatment Period
units on a scaleBDP HFA 80 µg/DayBDP HFA 160 µg/DayBDP HFA 320 µg/DayPlacebo
Change From Baseline in Morning 24-hour Reflective Non-nasal Symptom Score Over the Two-week Treatment Period-1.55 ± 0.22-1.49 ± 0.22-1.91 ± 0.21-1.51 ± 0.22
Statistical analysis
  • BDP HFA 80 µg/Day vs Placebo · Repeated measures ANCOVA · p = 0.903 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: 0.04 · 95% CI -0.64 to 0.57The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
  • BDP HFA 160 µg/Day vs Placebo · Repeated measures ANCOVA · p = 0.952 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: 0.02 · 95% CI -0.58 to 0.62The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.
  • BDP HFA 320 µg/Day vs Placebo · Repeated measures ANCOVA · p = 0.187 (A multiplicity adjustment procedure was implemented which allowed for control of the Type I error within a particular treatment comparison, as well as within a particular endpoint, however it did not control the overall Type I error.) · Ls mean difference: -0.40 · 95% CI -0.99 to 0.19The repeated measures ANCOVA included covariate adjustment for baseline, day, treatment, and the treatment by day interaction.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BDP HFA 80 µg/Day—0/118 (0%)6/118 (5.1%)
BDP HFA 160 µg/Day—2/123 (1.6%)3/123 (2.4%)
BDP HFA 320 µg/Day—0/122 (0%)3/122 (2.5%)
Placebo—0/123 (0%)1/123 (0.8%)
Most frequent serious events
Most frequent serious events
EventBDP HFA 80 µg/DayBDP HFA 160 µg/DayBDP HFA 320 µg/DayPlacebo
AngioedemaSkin and subcutaneous tissue disorders0/1181/1230/1220/123
Abortion spontaneous incompletePregnancy, puerperium and perinatal conditions0/1181/1230/1220/123
Most frequent other events
Most frequent other events
EventBDP HFA 80 µg/DayBDP HFA 160 µg/DayBDP HFA 320 µg/DayPlacebo
EpistaxisRespiratory, thoracic and mediastinal disorders6/1183/1233/1221/123

Baseline characteristics

Age Continuous
Age Continuous(years)BDP HFA 80 µg/DayBDP HFA 160 µg/DayBDP HFA 320 µg/DayPlaceboTotal
Mean37.6 ± 13.8639.8 ± 15.2638.5 ± 14.7438.2 ± 13.9538.5 ± 14.45
Sex: Female, Male
Sex: Female, Male(Participants)BDP HFA 80 µg/DayBDP HFA 160 µg/DayBDP HFA 320 µg/DayPlaceboTotal
Female76868173316
Male42374150170
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BDP HFA 80 µg/DayBDP HFA 160 µg/DayBDP HFA 320 µg/DayPlaceboTotal
White92999897386
Black2318221982
Asian250613
Other11215
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)BDP HFA 80 µg/DayBDP HFA 160 µg/DayBDP HFA 320 µg/DayPlaceboTotal
Hispanic or Latino1410171556
Not Hispanic or Latino104113105108430
Region of Enrollment
Region of Enrollment(participants)BDP HFA 80 µg/DayBDP HFA 160 µg/DayBDP HFA 320 µg/DayPlaceboTotal
United States118123122123486
08

Study locations

26 sites
  • Teva Global Respiratory Research Study Site
    Mission Viejo, California 92691, United States
  • Teva Global Respiratory Research Study Site
    San Diego, California 92120, United States
  • Teva Global Respiratory Research Study Site
    San Diego, California 92123, United States
  • Teva Global Respiratory Research Study Site
    Colorado Springs, Colorado 08907, United States
  • Teva Global Respiratory Research Study Site
    Denver, Colorado 08230, United States
  • Teva Global Respiratory Research Study Site
    Gainesville, Georgia 030501, United States
  • Teva Global Respiratory Research Study Site
    Savannah, Georgia 31406, United States
  • Teva Global Respiratory Research Study Site
    Indianapolis, Indiana 46208, United States
  • Teva Global Respiratory Research Study Site
    Overland Park, Kansas 66210, United States
  • Teva Global Respiratory Research Study Site
    Bethesda, Maryland 20814, United States
  • Teva Global Respiratory Research Study Site
    St. Louis, Missouri 63141, United States
  • Teva Global Respiratory Research Study Site
    Brick, New Jersey 08724, United States
  • Teva Global Respiratory Research Study Site
    Raleigh, North Carolina 27607, United States
  • Teva Global Respiratory Research Study Site
    Medford, Oregon 97504, United States
  • Teva Global Respiratory Research Study Site
    Portland, Oregon 97213, United States
  • Teva Global Respiratory Research Study Site
    Blue Bell, Pennsylvania 19422, United States
  • Teva Global Respiratory Research Study Site
    Pittsburgh, Pennsylvania 15241, United States
  • Teva Global Respiratory Research Study Site
    Upland, Pennsylvania 19013, United States
  • Teva Global Respiratory Research Study Site
    Charleston, South Carolina 29407, United States
  • Teva Global Respiratory Research Study Site
    Austin, Texas 78713, United States
  • Teva Global Respiratory Research Study Site
    Dallas, Texas 75231, United States
  • Teva Global Respiratory Research Study Site
    New Braunfels, Texas 78130, United States
  • Teva Global Respiratory Research Study Site
    San Antonio, Texas 78229, United States
  • Teva Global Respiratory Research Study Site
    Draper, Utah 84020, United States
  • Teva Global Respiratory Research Study Site
    Burke, Virginia 22015, United States
  • Teva Global Respiratory Research Study Site
    Richmond, Virginia 23233, United States
09

References and documents

Publications

  • Raphael GD, Berger WE, Prenner BM, Finn AF Jr, Kelley L, Tantry SK. Efficacy, safety, and optimal dose selection of beclomethasone dipropionate nasal aerosol for seasonal allergic rhinitis in adolescents and adults. Curr Med Res Opin. 2013 Oct;29(10):1329-40. doi: 10.1185/03007995.2013.821055. Epub 2013 Aug 6. PubMed 23815103 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 3 years after primary completion. A results delay was requested in Aug 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2009
First posted
Mar 3, 2009
Start
Mar 2009
Primary completionActual
May 2009
CompletionActual
May 2009
Results delay requested
Aug 25, 2011
Results first posted
May 22, 2012
Last update
May 22, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00854360
Responsible party
Sponsor
First posted
Mar 3, 2009
Start date
Mar 2009
Primary completion
May 2009
Completion
May 2009
Results posted
May 22, 2012
Last update
May 22, 2012

Study contacts

Sudeesh Tantry, Ph.D.
study chair · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion